Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma-Reference-Cited by-同舟云学术

Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma

Published:2018-03-12 Issue:4 Volume:184 Page:679-682
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Castillo Jorge J.¹^ORCID,Guerrero‐Garcia Thomas²,Baldini Francesco³,Tchernonog Emmanuelle⁴,Cartron Guillaume⁴,Ninkovic Slavisa⁵,Cwynarski Kate⁵,Dierickx Daan⁶,Tousseyn Thomas⁶,Lansigan Frederick⁷,Linnik Yevgeny⁷,Mogollon Renzo⁸,Navarro Jose‐Tomás⁹^ORCID,Olszewski Adam J.¹⁰^ORCID,Reagan John L.¹⁰^ORCID,Fedele Pasquale¹¹,Gilbertson Michael¹¹,Grigoriadis George¹¹,Bibas Michele³

Affiliation:

1. Division of Hematologic Malignancies Dana‐Farber Cancer Institute Harvard Medical School BostonMAUSA

2. Division of Hematology and Oncology Dana‐Farber Cancer Institute at St. Elizabeth's Medical Center Brighton MA USA

3. National Institute for Infectious Diseases Lazzaro Spallanzani Rome Italy

4. Department of Haematology CHU Montpellier Montpellier France

5. Department of Haematology UCLH London London UK

6. Department of Haematology University Hospitals Leuven Leuven Belgium

7. Division of Hematology and Oncology Dartmouth‐Hitchcock Medical Center Dartmouth Medical School Lebanon NH USA

8. Department of Medicine Universidad San Martin de Porres Lima Peru

9. Catalan Institute of Oncology German Trias I Pujol Hospital Badalona Spain

10. Division of Hematology and Oncology Rhode Island Hospital The Warren Alpert Medical School of Brown University Providence RI USA

11. Monash Haematology, Monash Medical Centre Monash University Clayton Australia

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.15156

Reference10 articles.

1. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas

2. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma

3. Human immunodeficiency virus-associated plasmablastic lymphoma

4. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma

5. The biology and treatment of plasmablastic lymphoma

Cited by 58 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Human immunodeficiency virus-associated lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up;Annals of Oncology;2024-10

2. Plasmablastic pituitary lymphoma in a patient with human immunodeficiency virus: brief review of the literature and clinical case report;Oncohematology;2024-09-03

3. Human immunodeficiency virus‐associated Lymphomas: EHA–ESMO Clinical Practice Guideline for diagnosis, treatment and follow‐up;HemaSphere;2024-09

4. Concurrent intestinal plasmablastic lymphoma and diffuse large B-cell lymphoma with a clonal relationship: a case report and literature review;Journal of Pathology and Translational Medicine;2024-07-15

5. Plasmablastic lymphoma: 2024 update on diagnosis, risk stratification, and management;American Journal of Hematology;2024-05-20